Scienture Holdings, Inc. (NASDAQ:SCNX – Get Free Report) was the target of a significant increase in short interest in July. As of July 15th, there was short interest totaling 2,600,386 shares, an increase of 177.8% from the June 30th total of 935,988 shares. Currently, 8.1% of the company’s shares are short sold. Based on an average daily volume of 7,329,646 shares, the days-to-cover ratio is currently 0.4 days.
Scienture Price Performance
SCNX stock traded down $0.01 during mid-day trading on Monday, hitting $0.36. 407,668 shares of the stock were exchanged, compared to its average volume of 2,208,575. The stock has a market capitalization of $14.71 million, a price-to-earnings ratio of -0.14 and a beta of 3.28. The business has a fifty day moving average price of $0.38 and a 200 day moving average price of $0.41. Scienture has a 12 month low of $0.24 and a 12 month high of $2.60.
Scienture (NASDAQ:SCNX – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.15. The business had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.40 million.
Analyst Ratings Changes
View Our Latest Analysis on Scienture
Hedge Funds Weigh In On Scienture
An institutional investor recently raised its position in Scienture stock. Geode Capital Management LLC boosted its stake in Scienture Holdings, Inc. (NASDAQ:SCNX – Free Report) by 264.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 316,201 shares of the company’s stock after purchasing an additional 229,398 shares during the period. Geode Capital Management LLC owned about 0.78% of Scienture worth $161,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.68% of the company’s stock.
About Scienture
Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.
See Also
- Five stocks we like better than Scienture
- AirJoule’s Kubota Deal Is a Major Validation—But the Hard Part Comes Next
- Dividend Stocks May Be the Quiet Rotation Trade Investors Are Missing Now
- Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?
- Verizon May Be an AI Infrastructure Stock Hiding in Plain Sight
Receive News & Ratings for Scienture Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scienture and related companies with MarketBeat.com's FREE daily email newsletter.
